N2OFF Rebrands to Nexentis Technologies, Pivoting to AI-Driven Biotech with New Ticker NXTS

summarizeSummary

N2OFF, Inc. announced a corporate rebranding to Nexentis Technologies Inc. and a new Nasdaq ticker, NXTS, effective February 26, 2026, signaling a strategic pivot to an AI and data-driven computational biotech platform.

check_boxKey Events

• Corporate Rebranding

  The company's name will change from N2OFF, Inc. to Nexentis Technologies Inc., effective February 26, 2026.

• New Ticker Symbol

  The trading symbol on the Nasdaq Capital Market will change from 'NITO' to 'NXTS', effective February 26, 2026.

• Strategic Business Pivot

  The rebranding reflects a strategic transformation into an innovative AI and data-driven computational biotech company, focusing on mitochondrial biology, precision oncology, and inflammatory metabolic diseases.

• Integration of MitoCareX

  This strategic shift is built upon the integration and scaling of MitoCareX Bio Ltd., now a wholly-owned subsidiary, which brings a proprietary discovery engine targeting mitochondrial SLC25 carrier family.

auto_awesomeAnalysis

N2OFF, Inc.'s rebranding to Nexentis Technologies Inc. and change of ticker to NXTS signifies a complete strategic pivot for the company. This move formalizes its transformation into an AI and data-driven computational biotech platform, focusing on mitochondrial biology, precision oncology, and inflammatory metabolic diseases. This strategic shift follows the acquisition of MitoCareX Bio Ltd. and aligns with the previously disclosed divestment of its Save Foods Ltd. stake, fundamentally redefining the company's core business and future direction. For a micro-cap company, such a comprehensive re-orientation is a highly material event, signaling a new investment thesis.